Main page2017-11-16T17:30:16+03:00
603, 2019

On the way to 90: Analysis of procurement and provision of ARV drugs in seven countries of Eastern Europe and Central Asia

06.03.2019|Monitoring of drug procurement, Monitoring of prices in the EECA region, News|0 Comments

ITPCru is proud to present its first regional report on procurement and provision of antiretroviral drugs in 7 countries of Eastern Europe and Central Asia in 2017. The report is based on a series of national reports implemented by patient organizations in the respective countries (Armenia, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Ukraine).

1705, 2018

Good news for people with HIV poster

17.05.2018|News, Материалы|0 Comments

We would like to present you our new poster in support of people with HIV who were recently diagnosed. It is called “Good news for people with HIV”. The poster contains separate blocks of information about differents aspects, for example, about a fact that effective treatment exists, people don’t die of HIV anymore, a lifespan is not limited by HIV, HIV

1809, 2017

Exit from the labyrinth: the end of decentralization. The results of monitoring of purchases of ARV drugs in Russia in 2016

18.09.2017|Monitoring of drug procurement, News|0 Comments

We are glad to present you the brief english version of the report “Exit from the labyrinth: the end of decentralization. The results of monitoring of purchases of ARV drugs in Russia in 2016”. The purpose of the report is to obtain conclusions based on the analysis of 4500 public procurement monitoring data for ARV drugs in 2016, and to

712, 2016

The meeting on the issues of intellectual property and access to treatment in EECA

07.12.2016|News|0 Comments

November 02-04 Tbilisi hosted a meeting dedicated to the issues of access to medicines in terms of the barriers associated with intellectual property. The meeting was attended by representatives from the following pharmaceutical companies: Pharmasyntez (Russia), Biocad (Russia), Cipla (India), Mylan (U.S.), Tatchempharm (Russia), and PharmEvo (Pakistan). The following issues have been discussed at the meeting:

1909, 2016

Hepatitis C treatment: recommendations 2016

19.09.2016|News, Материалы|1 Comment

The ITPCru team and SEVT Ltd. have developed a chart “Hepatitis C treatment: recommendations 2016” which includes the recent recommendations for interferon-free treatment of HCV-monoinfected (EASL 2016) and HCV/HIV coinfected patients (EACS 2016). The chart also contains updated tables with all approved direct-acting antiviral drugs, as well as information about drug-drug interactions (HCV/HIV drugs).